Obtaining regulatory approvals and commercialising innovative medtech is never easy. Yet equally, I’m becoming increasingly more confident that Avingtrans' (AVG) medical devices subsidiary Magnetica Limited will ultimately bring to market its grounding breaking small form, helium-free MRI scanner for the orthopaedics and veterinary sectors, which has a total addressable market of around £400m.

Today, Avingtrans said that it was upping its stake in the business from 61% to 74% via a debt-to-equity swap worth A$4.35m, or £2.5m, and a further A$6.21m (£3.5m) injection of share capital.

Here, both Avingtrans' CEO  Steve McQuillan and CFO Stephen King are highly accomplished directors and M&A experts. That suggests they would only be making such a follow-on investment (of around £6m) if they firmly believed there was good chance of delivering significant shareholder value.

Sure, there are still risks. But overall these look manageable and importantly more than offset by the possible substantial rewards. What’s more the extra funding is another perfect example of the Board’s PIE (Pinpoint-Invest-Exit) strategy. What's more, the money should be sufficient to finance Magnetica for the foreseeable future.

As such, I’m looking forward in hearing more at the interims on Wednesday 22nd February.